Lauren Cosolo, RN, BScN, MN
|
|
- Oliver Johnson
- 5 years ago
- Views:
Transcription
1 Bone Marrow Failure Diseases: Including MDS, AA, PNH Lauren Cosolo, RN, BScN, MN
2 Outline Review bone marrow failure and disease Discuss Myelodysplastic syndrome, pathophysiology, clinical presentation, diagnosis, treatment Discuss Aplastic Anemia, clinical presentation, diagnosis, treatment Discuss PNH, pathophysiology, clinical presentation, diagnosis, treatment Review nursing considerations for bone marrow failure diseases
3 Bone Marrow Failure Ineffective hematopoiesis causing pancytopenia and the inability to produce healthy blood cells Pancytopenia= reduction in blood counts red cells, white cells, platelets Image taken from: Scheinberg, DeZern, Steensma, 2016; Hoffbrand & Moss, 2016
4 Bone Marrow Failure Diseases Disorders resulting in cytopenia (low blood counts) due to decreased bone marrow production Can be congenital (inherited) or acquired disorders Congenital Fanconi anemia Diamond Blackfan anemia Dyskeratosis congenita Acquired Acquired Aplastic Anemia Myelodysplastic Syndrome (MDS) Paroxysmal Nocturnal Hemoglobinuria (PNH) Young, 2014; Zhang, 2016
5 Myelodysplastic Syndromes (MDS) Clonal disorders of hematopoietic stem cells characterized by increasing bone marrow failure in association with dysplastic changes (cells look abnormal) in one or more cell lineages Simultaneous proliferation and apoptosis of hematopoietic cells (ineffective hematopoiesis) leading to hypercellular bone marrow but pancytopenia in peripheral blood Pathologyoutline.com
6 Pathophysiology of MDS There is an abnormal regulation of proliferation, maturation and survival of hematopoietic stem cells due to genetic changes A number of genetic changes/mutations are associated with MDS Changes in the expression of genes, such as hypermethylation contributes to the development or progression of MDS Resulting in suppression of gene transcription As the disease progresses, maturation of stem cells are further impaired with increased survival of myeloblasts
7 Prevalence and Risk Factors MDS usually develops in older adults >60 years old with median age of years More common in males than in females MDS relatively common disease 4-7 estimated new cases/100,000 each year Risk Factors: Older age Male Exposure to environmental factors (benzene) Smoking Previous chemotherapy or radiation treatment Buckstein & Wells, 2008
8 Etiology De novo MDS Idiopathic Environmental exposure Benzene, solvents, agriculture chemicals Smoking Autoimmune disorders Viral illnesses Inherited genetic abnormalities Other benign hematologic diseases Treatment-related MDS Chemotherapeutic agents Radiation therapy Devine, 2013; Aster & Stone, 2018
9 Clinical Presentation Patients with MDS typically present with peripheral blood cytopenias Patients range from being asymptomatic with an incidental CBC finding to having symptoms and complications related to the previously unrecognized cytopenia Majority of MDS patients present with red cell lineage dysplasia (anemia) Signs and Symptoms include: Fevers, infection from neutropenia Petechiae, ecchymosis, bruising, bleeding from thrombocytopenia Fatigue, SOB, palpitations, weakness, exercise intolerance, dizziness, pale complexion, cognitive impairment as result of anemia
10 Diagnosis Diagnosis of MDS dependent on: 1. Quantitative changes in blood elements (cytopenias) 2. Evidence of dysplasia in peripheral blood smear and marrow History Signs and symptoms Past medical history + comorbidities Blood transfusion history Prior chemotherapy/radiation treatment Family history Medications Exposure to chemicals Physical Exam Investigating for evidence of cytopenias Integumentary Mucous membranes Bleeding- epistaxis, gum bleeding, hemoptysis, hematuria, prolonged menstruation, melena Fatigue Vital signs Presence of fevers, infections Presence of splenomegaly
11 Diagnostic Investigations Blood work Initial workup for MDS: CBC with blood smear, reticulocyte count, iron TIBC Ferritin, LDH level, EPO level Initial workup to rule out other causes of cytopenia Peripheral Blood Smear Dysplasia in red and white blood cells and platelets Bone Marrow Biopsy and Aspirate Aspirate will allow to evaluate morphology of hematopoietic precursors and blasts and cytogenetics (Identification of abnormal chromosomes (ie. 5q- del) and for prognosis) Biopsy will show cellularity (usually increased, sometimes hypocellular bone marrow seen in MDS) Flow Cytometry Findings can suggest clonality and presence of MDS Used especially when dysplasia is minimal and cytogenetics is normal
12 WHO Classification of MDS Subtype Peripheral blood Bone marrow % blasts Refractory anemia Anemia Unilineage erythroid dysplasia (in >10% cells) Refractory neutropenia Neutropenia Unilineage granulocytic dysplasia Refractory thrombocytopenia Refractory anemia with ring sideroblasts (RARS) Refractory cytopenia with multilineage dysplasia (RCMD) Refractory anemia with excess blasts type 1 (RAEB-1) Refractory anemia with excess blasts type 2 (RAEB-2) MDS associated with isolated del (5q-) Thrombocytopenia Anemia Cytopenia Cytopenia Cytopenia Anemia, normal or high platelet count Unilineage megakaryocytic dysplasia Unilineage erythroid dysplasia >15% erythroid precursors are ring sideroblasts Multilineage dysplasia +/- ring sideroblasts Unilineage or multilineage dysplasia Unilineage or multilineage dysplasia 5q31 deletion, anemia, hypolobulated megakaryocytes <5 <5 <5 <5 < <5
13 IPSS-R Parameter Cytogenetic risk group Categories and Associated Scores Very good Good Intermediate Poor Very poor Marrow Blast proportion 2% >2-<5% 5-10% >10% Hemoglobin 10g/dL 8-<10g/dL <8 g/dl ANC 0.8 x 10 9 /L <0.8 x 10 9 /L Platelet Count 100 x 10 9 /L x 10 9 /L <50 x 10 9 /L Tool is only helpful at time of diagnosis Tool is used to estimate life expectancy for NEWLY diagnosed patients with MDS Risk Category Risk Score Very low 1.5 Low >1.5-3 Intermediate >3-4.5 High >4.5-6 Very high >6
14 IPSS-R
15 Prognosis Factors that predict outcome include: WHO classification Complex karyotype (>3 chromosome abnormalities) Chromosome abnormalities Blast proportion Cytopenias Even low risk MDS has significant morbidity and mortality including transfusion requirements and associated complications Worsening of pancytopenia, acquisition of chromosomal abnormalities, increase in number of blasts are poor prognostic indicators Therapy related MDS is an extremely poor outlook
16 Treatment Dependent on: Patient s age Performance status Prognostic score WHO classification comorbidities Determine treatment goals with patient and family, including achieving hematologic improvement, reducing transfusion requirements, delaying transformation to leukemia, improving survival and maintaining quality of life Devine, 2013
17 Low Risk MDS Treatment Options (IPSS Low Risk/Int Risk-1) For patients that are asymptomatic watchful waiting and monitor Q3-6 months Symptomatic Treatment options Medications for anemia (ESA, lenalidomide), neutropenia (antibiotics, GCSF), thrombocytopenia (antifibrinolytics) Immunosuppressive therapy (ATG, Cyclosporine) Supportive Care (transfusion support, iron chelation) Allo-SCT assessment Delayed allo-sct offers maximal life expectancy as long as transplant occurs before transformation to leukemia Eligibility ultimately decided by transplant center Often SCT is not an option to due to patients older age or comorbidities Mdsclearpath.org
18 Disease Progression Potential indicators of progression to high risk MDS Worsening cytopenia New cytopenia Appearance of blasts Rising LDH Systemic symptoms (fever, weight loss) Specific evaluation of higher risk MDS Bone marrow aspiration and biopsy Flow cytometry Cytogenetics Mdsclearpath.org
19 Treatment Options for High Risk MDS Goal of treatment: Change natural history of MDS Defer AML transformation Improve survival for patients with MDS Treatment Options: Hypomethylating agents (azacitidine, decitabine) (usually standard of care, however not a cure for MDS) Chemotherapy Allogeneic Stem Cell Transplant Supportive Care/ Palliative Care Clinical Trial Mdsclearpath.org
20 Supportive Care All patients should receive supportive care as it is adjunct to chosen therapy Patients with cytopenias and associated symptoms can receive supportive care Transfusion support Red cells or platelets CMV negative Nursing Management: Identify symptoms of anemia, monitor CBC, monitor for fluid overload and advocate for diuretic Assess response to platelet transfusions (platelet refractoriness) and PRBCS (Hgb) Monitor for SE of transfusions Iron overload Mdsclearpath.org
21 Iron Overload Management Iron Chelation Therapy Deferoxamine SC daily dose of 1,000 2,000 mg (20 40 mg/kg/day) should be administered over 8 24 hours, using a small portable pump capable of providing continuous mini-infusion. SE: allergic reaction, ocular and ototoxicity, cardiac dysfunction pretreatment hearing and visual exam Defersirox Initial dose 20 mg/kg body weight daily, orally, taken on an empty stomach 30 minutes prior to meals. SE: GI hemorrhage, hepatic/renal failure, cytopenias, diarrhea, n/v, abdo pain Deferiprone SE: agranulocytosis Measure ANC, interrupt if ANC <1.5
22 Impact of MDS on Patients/Families Quality of life is complex, individually defined for patients living with MDS Includes physical, social, emotional, practical and spiritual aspects Aging, comorbidities, fatigue, and uncertain illness trajectory affects the quality of life of patients Oncology nurses are in an appropriate position to monitor the impact of the illness and treatment on patients and their quality of life through systematic assessment, providing appropriate interventions, referrals and ongoing support Thomas, Crisp & Campbell,2012
23 Aplastic Anemia Pancytopenia (low blood counts) as a result of hypoplasia of bone marrow Can be inherited or acquired, majority are acquired Reduction in number of hematopoietic stem cells and an immune reaction or error in the remaining stem cells causing them to not divide or differentiate appropriately to populate bone marrow Image: Medical-dictionary.thefreedictionary.com; Hoffbrand & Moss, 2016
24 Prevalence and Etiology Affects primarily children (with children, majority are inherited), young adults or adults >60 More common in people of Asian descent 2-12 new cases/million each year Etiology: Inherited or acquired Most cases are idiopathic Exposure to chemicals, drugs, viruses, radiation, immune diseases Incekol & Ghadimi, 2015; Hoffbrand & Moss, 2016
25 Clinical Features Present with signs and symptoms of pancytopenia Most frequent symptoms: Bruising Bleeding gums Epistaxis Menorrhagia Symptoms of anemia (Pallor, headache, palpitation, SOB/dyspnea, fatigue, foot swelling) Infections are common and frequently life threatening Incekol & Ghadimi, 2015; Hoffbrand & Moss, 2016
26 Diagnosis Blood work CBC with diff, B12, folic acid, LFT, LDH, chem panel, coags Pancytopenia early on Bone Marrow Aspirate and Biopsy Bone marrow is profoundly hypocellular, marrow space is composed mostly of fat cells and marrow stroma Flow cytometry To detect coexisting disorders Cytogenetics Rule out MDS and congenital disorders
27 Classification Severe Presence of 2-3 parameters: ANC <0.5 Platelets <20 Reticulocytes <1% Very Severe ANC <0.2 Non-Severe Not fulfilling severity criteria Chronic needs >3 months
28 Treatment very severe & severe aplastic anemia stages require treatment as this category has a high mortality rate HCT ( hematopoeitic stem cell therapy) Dependant on age, functional status and availability of donor Immunosuppressive therapy ATG (Antithymocyte globulin) Horse ATG administered IV over 4 days Requires pre-medication with tylenol/ benadryl to decrease infusion reactions and serum sickness reaction Requires daily steroids to reduce risk of serum sickness Risk for anaphylaxis- keep anaphylaxis kit at bedside during infusion Cyclosporine SE: HTN, renal insufficiency, Mg deficiency, gum hyperplasia Requires BP, Cr monitoring, regular dental care Larratt, powerpoint; Longo, 2017
29 Serum Sickness Occurs 1-2 weeks after initiating treatment of ATG Flu-like illness, rash and arthralgia Treatment: steroids
30 Supportive Care Transfusions RBC, platelets Irradiated Blood Treatment of Infections Empiric therapy with broad spectrum antibiotics Growth factors as prophylaxis for repeated infections Infection Prevention and Monitoring Patient education on preventing infections and monitoring for fever and signs and symptoms of infection
31 Paroxysmal Nocturnal Hemoglobinuria (PNH) Acquired hemolytic anemia Characterized by: Hemolysis Venous Thrombosis Pancytopenia Longo, 2017
32 Pathophysiology Acquired mutation in PIG-A gene in hematopoietic stem cell If mutation proliferates the result is a clone that is deficient in cell surface proteins known as glycosylphospatidylinositolanchored proteins (GPI-AP) The GPI-AP proteins act as receptors, complement regulators and adhesion molecules CD55 and CD59 which are two GPI-AP that protect red blood cells from complement activity are not present on the surface of the PNH red blood cells, which leaves these cells extremely sensitive to complement-mediated destruction Young et al., 2009
33 Prevalence Same frequency in men and women Rare disease Prevalence estimated at 5/1,000,000 Can present in small children or older adults, most patients are young adults
34 Clinical Presentation Anemia Results from a combo of hemolysis and bone marrow failure Thrombosis Common sites: intraabdominal( hepatic, portal, mesenteric, splenic) and cerebral veins with hepatic vein thrombosis (Budd-Chiari syndrome) Gastrointestinal Abdominal pain, esophageal spasm, dysphagia Other Manifestations Gross hemoglobinuria, renal tubular damage Brodsky, 2014
35 Diagnosis Blood work CBC with diff Liver profile, bilirubin LDH Reticulocyte count Urinalysis Hemoglobinuria Flow Cytometry Identify the GPI-AP deficient peripheral blood cells Parker et al., 2005
36 Treatment Supportive Care Transfusions Folic acid/iron supplements Treatment of complications (eg. Thrombosis) Biotherapy Ecullizumab (Solaris) Allogenic SCT for young patient with severe PNH Primary prophylaxis for thrombosis Longo, 2017
37 Nursing Considerations for Bone Marrow Failure Diseases Comprehensive assessment of patient and management of side effects Monitoring for signs and symptoms of cytopenias including fatigue, bleeding, infection, etc. and providing appropriate interventions Addressing patient s supportive care needs Education for patients and families on understanding the disease and its manifestations, treatment modalities and the adverse effects from treatment Connect to hospital and community resources
38 AAMAC Telephone and patient-to-patient support Educational material on Aplastic Anemia, MDS & PNH Quarterly newsletter Patient Tracker Local support group meetings Grants for medical research and education Website, Facebook, Marrowforums
39 References Devine, H. (2013). Myelodysplastic syndromes. In M. Olsen & L. Zitella (Eds.), Hematologic Malignancies in Adults (51-74). Pittsburgh, Pennsylvania: Oncology Nursing Society. Buckstein, R. & Wells, R. (2008). Myelodysplastic syndromes (MDS). Retrieved from: Burgoyne, T. & Knight, A. (2000). Myelodysplastic syndromes. In M. Grundy (Ed.), Nursing in Hematological Oncology (21-30). London, UK: Baillere Tindall Royal College of Nursing Celgene. (2010). Vidaza azacitidine for injection. Thomas, M.L., Crisp, M., & Campbell, K. (2012). The importance of quality of life for patients living with myelodysplastic syndrome. Clinical Journal of Oncology Nursing, 16(3), Van de Loosdrecht, A. A., & Westers, T. M. (2014). Flow Cytometric Immunophenotyping in Myelodysplasia: Discovery and Diagnosis. Blood, 124(21), SCI-24. Accessed June 24, Retrieved from Incekol, D. & Ghadimi, L. (2015). Princess Margaret cancer centre: malignant hematology: self-learning booklet. 3 rd edition. Longo, D.L. (2017). Harrison s hematology and oncology. New York: McGraw-Hill Education Brodsky, R. A. (2014). Paroxysmal nocturnal hemoglobinuria. Blood, 124, Parker, C. et al. (2005). Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood, 106, Young, N.S. et al. (2009). The management of paroxysmal nocturnal hemoglobinuria: recent advance in diagnosis and treatment and new hope for patients. Seminars in Hematology, 46(1), S1-S6
40 References Hoffbrand, A.V. & Moss, P. A.H. (2016). Hoffbrand s Essential Haematology. West Sussex, UK: Wiley & Sons, Ltd. MDS Clear Path. Mdsclearpath.org Scheinberg, P., DeZern, A.E. & Steensma, D.P. (2016). Acquired bone marrow failure syndromes: aplastic anemia, paroxysmal hemoglobinuria, and myelodysplastic syndromes. Retrieved from: tm_medium=cpc&utm_campaign=american_society_of_hematology_self- Assessment_Program_TrendMD_0 Young NS. Young N.S. Young, Neal S.Bone Marrow Failure Syndromes Including Aplastic Anemia and Myelodysplasia. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J Eds. Dennis Kasper, et al.eds. Harrison's Principles of Internal Medicine, 19e New York, NY: McGraw-Hill; Accessed August 01, Zhang, L. (2016). Inherited and acquired bone marrow failure syndromes: in the era of deep gene sequencing. Journal of Leukemia, 4(4)
Myelodysplastic Syndrome: Let s build a definition
1 MDS: Diagnosis and Treatment Update Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian Hospital Myelodysplastic
More informationMYELODYSPLASTIC SYNDROMES: A diagnosis often missed
MYELODYSPLASTIC SYNDROMES: A diagnosis often missed D R. EMMA W YPKEMA C O N S U LTA N T H A E M AT O L O G I S T L A N C E T L A B O R AT O R I E S THE MYELODYSPLASTIC SYNDROMES DEFINITION The Myelodysplastic
More informationMDS 101. What is bone marrow? Myelodysplastic Syndrome: Let s build a definition. Dysplastic? Syndrome? 5/22/2014. What does bone marrow do?
101 May 17, 2014 Myelodysplastic Syndrome: Let s build a definition Myelo bone marrow Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine What is bone marrow? What does bone
More informationMDS: Who gets it and how is it diagnosed?
MDS: Who gets it and how is it diagnosed? October 16, 2010 Gail J. Roboz, M.D. Director, Leukemia Program Associate Professor of Medicine Weill Medical College of Cornell University The New York Presbyterian
More informationThe function of the bone marrow. Living with Aplastic Anemia. A Case Study - I. Hypocellular bone marrow failure 5/14/2018
The function of the bone marrow Larry D. Cripe, MD Indiana University Simon Cancer Center Bone Marrow Stem Cells Mature into Blood Cells Mature Blood Cells and Health Type Function Term Red Cells Carry
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationTable 1: biological tests in SMD
Table 1: biological tests in SMD Tests Mandatory Recommended Under validation Morphology Marrow aspirate Marrow biopsy 1 Iron staining Quantification of dysplasia WHO 2008 Classification Cytogenetics Conventional
More informationMYELODYSPLASTIC SYNDROME. Vivienne Fairley Clinical Nurse Specialist Sheffield
MYELODYSPLASTIC SYNDROME Vivienne Fairley Clinical Nurse Specialist Sheffield MDS INCIDENCE 1/100,000/YEAR 3,250/YEAR MEDIAN AGE 70 MDS HYPO OR HYPERCELLULAR BONE MARROW BLOOD CYTOPENIAS (EARLY STAGES
More informationOverview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017
Overview of Aplastic Anemia Overview of Aplastic Anemia Peter Westervelt, MD, PhD Professor of Medicine Chief, BMT/Leukemia Section Washington University School of Medicine Epidemiology Normal hematopoiesis
More informationOutline. What is aplastic anemia? 9/19/2012. Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options
Aplastic Anemia Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Options Carlos M. de Castro, MD Duke University Medical Center Outline What is Aplastic Anemia? What other diseases
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationMDS - Diagnosis and Treatments. Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital
MDS - Diagnosis and Treatments Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital Overview What is myelodysplasia? Symptoms Diagnosis and prognosis Myelodysplasia therapy
More informationPathophysiology 7/18/2012 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA OUTLINE OF DISCUSSION WHAT IS IT WHO GETS IT NATURAL HISTORY TYPES RISKS COURSE TREATMENTS SYMPTOMS PREGNANCY Pathophysiology Acquired hematopoietic stem cell disorder
More informationAplastic Anemia: Understanding your Disease and Treatment Options
Aplastic Anemia: Understanding your Disease and Treatment Options No financial relationships or commercial interest related to the content of this presentation Josh Sasine, MD, PhD Hematopoietic Cell Transplant
More informationBor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital
Bor-Sheng Ko Hematology Division, Department of Internal Medicine, National Taiwan University Hospital On behalf of Members of Aplastic Anemia Consensus Meeting Diagnosis and classification: Treatment
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationMyelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support
Myelodysplastic Syndromes (MDS) Diagnosis, Treatments & Support LLS Mission & Goals Our mission. Cure leukemia, lymphoma, Hodgkin s disease and myeloma, and improve the quality of life of patients and
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More information7/24/2017. MDS: Understanding Your Diagnosis and Current and Emerging Treatments. Hematopoiesis = Blood Cell Production
: Understanding Your Diagnosis and Current and Emerging Treatments Erica Warlick, MD Associate Professor of Medicine Division of Hematology, Oncology, and Transplantation University of MN Objectives Overview
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationHow I treat acquired aplastic anemia
How I treat acquired aplastic anemia Phillip Scheinberg and Neal S. Young Blood Volume 120(6):1185-1196 August 9, 2012 2012 by American Society of Hematology Symptoms, Signs, and Lab Findings Bruising,
More information2013 AAIM Pathology Workshop
2013 AAIM Pathology Workshop John Schmieg, M.D., Ph.D. None Disclosures 1 Pathology Workshop Objectives Define the general philosophy of reviewing pathology reports Review the various components of Bone
More informationLiving with PNH 7/3/2013. Paroxysmal Nocturnal Hemoglobinuria (PNH): A Chronic, Systemic, and Life- Threatening Disease
Living with PNH Laurence A. Boxer, MD University of Michigan Case Study 15 year old awakened in the morning with chest pain and a sore throat. She experienced chest pain all day accompanied with coughing
More informationAplastic Anemia Pathophysiology and Approach to Therapy
Aplastic Anemia Pathophysiology and Approach to Therapy BSMCON 2018 Dr. Syed Ghulam Mogni Mowla MBBS, FCPS, FACP Introduction Aplastic anaemia (AA) is the paradigm of the human bone marrow failure syndromes
More informationLet s Look at Our Blood
Let s Look at Our Blood Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC 10,000,000,000 WBCs/day Bone Marrow: The Blood
More informationSESSION 1 Reactive cytopenia and dysplasia
SESSION 1 Reactive cytopenia and dysplasia Falko Fend, Tübingen & Alexandar Tzankov, Basel 1 Disclosure of speaker s interests (Potential) conflict of interest none Potentially relevant company relationships
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationWhen Cancer Looks Like Something Else: How Does Mutational Profiling Inform the Diagnosis of Myelodysplasia?
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationMyelodysplastic syndromes
Haematology 601 Myelodysplastic syndromes The myelodysplastic syndromes are a group of disorders predominantly affecting elderly people, leading to ineffective haematopoiesis, and they have the potential
More informationMyelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management
Myelodysplastic Syndromes (MDS) Enhancing the Nurses Role in Management Christa Roe, RN, BS, OCN Malignant Hematology Department H Lee Moffitt Cancer Center & Research Tampa, Florida Agenda MDS Disease
More informationYear 2002 Paper two: Questions supplied by Jo 1
Year 2002 Paper two: Questions supplied by Jo 1 Question 70 A 25 year old previously well male student presents with recent exertional dyspnoea, epistaxis and bruising. There is no history of medication,
More informationAnemia (3).ms4.25.Oct.15 Hemolytic Anemia. Abdallah Abbadi
Anemia (3).ms4.25.Oct.15 Hemolytic Anemia Abdallah Abbadi Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k, retics 12%, LDH
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationPediatrics. Aplastic Anemia in Children Prognosis and Survival Rate. Definition of Aplastic Anemia. See online here
Pediatrics Aplastic Anemia in Children Prognosis and Survival Rate See online here Aplastic anemia is a rare disease affecting 1 2 people per one million of the population. The hallmark of the disease
More informationParoxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria Barry Skikne MD, FACP, FCP(SA) Professor of Hematology Division of Hematologic Malignancies and Cellular Therapeutics Cardinal Clinical Manifestations PNH Clonal disease
More informationSOLIRIS (eculizumab) Slide # 1. How do we treat PNH?
Treating PNH How do we treat PNH? Hemolytic anemia Iron, folic acid Transfusion Steroids Eculizumab Thrombosis Coumadin prophylaxis Acute treatment with lytic agents (clot busters) Anticoagulation therapy
More information9/9/2015 HISTORY & EPIDEMIOLOGY. Objectives. Textbook Definition of Aplastic anemia (AA) Epidemiology. History
Objectives Aplastic Anemia: Current Thinking on the Disease, Diagnosis, and Non-Transplant Treatment Amy E. DeZern, MD, MHS Assistant Professor of Oncology and Medicine The Johns Hopkins University School
More informationImpact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Current Therapeutic and Biologic Advances in MDS A Symposium of The MDS Foundation ASH 2014 Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS Peter Valent Medical University of Vienna
More informationAnemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh
Anemia (3).ms4.26.2.18 Hemolytic Anemia Abdallah Abbadi Feras Fararjeh Case 3 24 yr old female presented with anemia syndrome and jaundice. She was found to have splenomegaly. Hb 8, wbc 12k, Plt 212k,
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationAPPROACHING TO PANCYTOPENIA
APPROACHING TO PANCYTOPENIA P A T C H A R E E K O M V I L A I S A K, M. D. A S S I S T A N T P R O F E S S O R D I V I S I O N O F P E D I A T R I C H E M A T O L O G Y O N C O L O G Y, D E P A R T M E
More informationTreating Higher-Risk MDS. Case presentation. Defining higher risk MDS. IPSS WHO IPSS: WPSS MD Anderson PSS
Treating Higher-Risk MDS Eyal Attar, M.D. Massachusetts General Hospital Cancer Center eattar@partners.org 617-724-1124 Case presentation 72 year old man, prior acoustic neuroma WBC (X10 3 /ul) 11/08 12/08
More informationMyelodysplastic Syndromes
Myelodysplastic Syndromes Jennifer Rogers MS, FNP Cancer Center of the Carolinas Greenville, SC The Myelodysplastic Syndromes Overview Clonal disorder characterized by hypercellular marrows, peripheral
More informationAnemia. A case-based approach. David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017
Anemia A case-based approach David B. Sykes, MD, PhD Hematology, MGH Cancer Center June 8, 2017 Recognizing trends Learning Objectives MCV, RDW, Ferritin, LDH, Reticulocytes Managing complex patients 1.
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationA prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.
Protocol Synopsis Study Title A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes. Short Title European MDS
More informationAbout Myelodysplastic Syndromes
About Myelodysplastic Syndromes Overview and Types If you have been diagnosed with a myelodysplastic syndrome or are worried about it, you likely have a lot of questions. Learning some basics is a good
More informationUnderstanding & Treating Myelodysplastic Syndrome (MDS)
Understanding & Treating Myelodysplastic Syndrome (MDS) Casey O Connell, MD Associate Professor of Clinical Medicine Jane Anne Nohl Division of Hematology Keck School of Medicine of USC Let s Look at Our
More informationAcute Myeloid Leukemia: A Patient s Perspective
Acute Myeloid Leukemia: A Patient s Perspective Patrick A Hagen, MD, MPH Cardinal Bernardin Cancer Center Loyola University Medical Center Maywood, IL Overview 1. What is AML? 2. Who gets AML? Epidemiology
More informationMyelodysplastic syndrome. Jeanne Palmer, MD Mayo Clinic, Arizona
Myelodysplastic syndrome Jeanne Palmer, MD Mayo Clinic, Arizona What is Myelodysplastic syndrome? A disease where the bone marrow doesn t work appropriately What does that mean?? Red blood cells Carry
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationMyelodysplastic Syndrome
Myelodysplastic Syndrome A Family-Oriented Approach on Diagnosis and Treatment Options Cecilia Arana Yi, MD Assistant Professor MDS Patient & Family/Caregiver Forum March 3, 2018 Quote of the Day There
More informationAplastic Anemia: Current Thinking
Aplastic Anemia: Current Thinking ANDREW C. DIETZ, MD, MSCR PEDIATRIC BLOOD AND MARROW TRANSPLANTATION CHILDREN S HOSPITAL LOS ANGELES, UNIVERSITY OF SOUTHERN CALIFORNIA Outline Ø What is Aplastic Anemia?
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationRory McCulloch. Specialty Trainee Haematology Royal Devon & Exeter Hospital
Rory McCulloch Specialty Trainee Haematology Royal Devon & Exeter Hospital Anaemia 1 Haematological disorders Anaemia 2 Non-haematological disorders Substrates: Iron, folate, vitamin B12 Red cell mass
More informationCASE 106. Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation
CASE 106 Pancytopenia in the setting of marrow hypoplasia, a PNH clone, and a DNMT3A mutation Gabriel C. Caponetti, MD University of Pennsylvania, US Clinical history 69, F peripheral neuropathy, refractory
More informationCorrespondence should be addressed to Anas Khanfar;
Case Reports in Oncological Medicine, Article ID 949515, 4 pages http://dx.doi.org/10.1155/2014/949515 Case Report Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion
More informationMyelodysplastic Syndromes Myeloproliferative Disorders
Myelodysplastic Syndromes Myeloproliferative Disorders Myelodysplastic Syndromes characterized by maturation defects that are associated with ineffective hematopoiesis and a high risk of transformation
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationGuidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS)
Guidelines for diagnosis and management of Adult Myelodysplastic Syndromes (MDS) Author: Dr A Pillai, Consultant Haematologist On behalf of the Haematology CNG Re- Written: February 2011, Version 2 Revised:
More informationACCME/Disclosures. History. Hematopathology Specialty Conference Case #4 4/13/2016
Hematopathology Specialty Conference Case #4 Sherrie L. Perkins MD, PhD University of Utah ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationAcute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration
Acute haemolysis and appearance of PNH-like clones in patients with vitamin B12 deficiency and iron deficiency after iron dextran administration Chun-Liang Lin 1, Chin-Chan Lin 1,Wen-Jyi Lo 2,Yu-Chien
More informationAllogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
More informationPROMACTA (eltrombopag olamine) oral tablet and oral suspension
PROMACTA (eltrombopag olamine) oral tablet and oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationMyelodysplastic scoring system with flow cytometry. G Detry B Husson
Myelodysplastic scoring system with flow cytometry G Detry B Husson Myelodysplastic syndroms Clonal haematopoietic stem cell disease characterized by dysplasia in one or more of the myeloid cell lines
More informationRAEB-2 2 Transforming to Acute Erythroleukemia Case # 165
RAEB-2 2 Transforming to Acute Erythroleukemia Case # 165 Sebastian J. Sasu, M.D. UCLA Medical Center, Hematopathology Los Angeles, CA and Saint John s s Health Center Santa Monica, CA Clinical History
More informationDisclosers Updates: Management of Aplastic Anemia and Congenital Marrow Failure 5/9/2017
2017 Updates: Management of Aplastic Anemia and Congenital Marrow Failure Sachit Patel, MD Department of Pediatrics Division of Hematology-Oncology Blood and Marrow Transplantation Disclosers None 1 Objectives:
More informationDarbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes
NIHR Innovation Observatory Evidence Briefing: August 2017 Darbepoetin alfa (Aranesp) for treatment of anaemia in adults with low or intermediate-1-risk myelodysplastic syndromes NIHRIO (HSRIC) ID: 13763
More informationChanges to the 2016 WHO Classification for the Diagnosis of MDS
Changes to the 2016 WHO Classification for the Diagnosis of MDS Welcome to Managing MDS. I am Dr. Ulrich Germing, and today, I will provide highlights from the 14th International Symposium on MDS in Valencia,
More informationMYELOPROLIFERATIVE DISEASE. Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG
MYELOPROLIFERATIVE DISEASE Dr Mere Kende MBBS (UPNG), MMED (Path),MAACB, MACTM, MACRRM (Aus) Lecturer-SMHS UPNG Myeloproliferative Diseases Essential to diagnosis Acquired clonal abnormalities of the hematopoietic
More informationWestwood Kansas Forum November 7, 2015 Part 1 Page 1 of 13
Westwood Kansas Forum November 7, 2015 Part 1 Page 1 of 13 Speakers: Suman Kambhampati, MD Jean Ridgeway, DNP, APN, NP-C, AOCN Suman Kambhampati, MD: The purpose of today s talk is basically to give you
More informationLeukemia and Myelodysplastic Syndromes
Leukemia and Myelodysplastic Syndromes Lenise Taylor, RN, MN, AOCNS Heme Malignancies/BMT CNS Seattle Cancer Care Alliance/UWMC Lymphoid 1 Myeloid 2 Presenting Signs and Symptoms Diagnostic Evaluation
More informationClinical Guidelines for Leukaemia and other Myeloid Disorders MDS
Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS Reference Number Version Status Executive Lead(s) Name and Job Title Author(s) Name and Job Title 13-2H-106 2 Dr Helen Barker MDT Lead
More informationMyelodysplastic Syndrome Early Detection, Diagnosis, and Staging
Myelodysplastic Syndrome Early Detection, Diagnosis, and Staging Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that
More informationPlatelet and WBC disorders
Division of Family Practice Platelet and WBC disorders Adrian Yee MD FRCPC Clinical hematologist Assistant Dean, undergraduate education, IMP asyee@uvic.ca When we understand that slide, we'll have won
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationMyelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression
Myelodysplastic Syndromes: Hematopathology. Analysis of SHIP1 as a potential biomarker of Disease Progression Carlos E. Bueso-Ramos, M.D., Ph.D Department of Hematopathology The University of Texas M.
More informationThe use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
VOLUME 45 ㆍ NUMBER 4 ㆍ December 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The use of the complement inhibitor eculizumab (Soliris R ) for treating Korean patients with paroxysmal nocturnal
More information3/31/2014. New Directions in Aplastic Anemia Treatment: What s on the Horizon? Objectives
New Directions in Aplastic Anemia Treatment: What s on the Horizon? AA & MDS International Foundation Living with, MDS, or PNH Patient and Family Conferences in 2014 April 5, 2014 Objectives To provide
More informationAplastic anamia & Sideroblastic anemia
Hematology Lecture 7 كلية التقنيات الصحية والطبية قسم التحليالت المرضية Aplastic anamia & Sideroblastic anemia اإلعداد: ظفر جبار دهاق فؤاد APLASTIC ANEMIA What is Aplastic anemia? Aplastic anemia is a
More informationNetwork Guidance Document. Oncological treatment of Haematology. Myelodysplastic Syndromes (MDS) Final. Status: November 2012.
Network Guidance Document Oncological treatment of Haematology Myelodysplastic Syndromes (MDS) Status: Final Expiry Date: November 2012 Version Number: 1 Publication Date: November 2010 Page 1 of 14T:\DOG
More information74y old Female with chronic elevation of Platelet count. August 18, 2005 Faizi Ali, MD Hematopathology Fellow
74y old Female with chronic elevation of Platelet count August 18, 2005 Faizi Ali, MD Hematopathology Fellow Clinical History Patient is a 74y old otherwise healthy Caucasian female with no major complaint
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationINHERITED PANCYTOPENIA SYNDROMES Fanconi anemia Shwachman-Diamond syndrome Dyskeratosis congenita Congenital amegakaryocytic thrombocytopenia
The Pancytopenias The Inherited Pancytopenias Pancytopenia refers to a reduction below normal values of all 3 peripheral blood component: leukocytes, platelets, and erythrocytes. Pancytopenia requires
More informationLa lenalidomide: meccanismo d azione e risultati terapeutici. F. Ferrara
La lenalidomide: meccanismo d azione e risultati terapeutici F. Ferrara MDS: new treatment goals Emerging treatment options expected to facilitate shift from supportive care to active therapy in MDS New
More informationThis is a controlled document and therefore must not be changed
AZACITIDINE NICE TA218 Treatment of adults not eligible for haematopoietic stem cell transplantation who have: Intermediate-2 and high-risk MDS according to the International Prognostic Scoring System
More informationMyelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management
Received: 2 October 2017 Accepted: 2 October 2017 DOI: 10.1002/ajh.24930 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationMyelodysplastic Syndromes
Please complete our online survey at NCCN GUIDELINES FOR PATIENTS NCCN.org/patients/survey 2018 Myelodysplastic Syndromes Presented with support from: Available online at NCCN.org/patients Ü Myelodysplastic
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology April 2018 Clinical Consequences of Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia: A Multidisciplinary Discussion PLUS
More informationBorderline cytopenias. Dr Taku Sugai Consultant Haematologist
Borderline cytopenias Dr Taku Sugai Consultant Haematologist Borderline cytopenias Neutropenia Thrombocytopenia Anaemia with normal haematinics Two recent cases of cytopenias Neutropenia ANC of more than
More information